advertisement

New! WalletPop

Markets

U.S. open in 15 hrs, 8 mins

9,447.11

-508.39

5.11%

1,754.88

-108.08

5.80%

996.23

-60.66

5.74%

104.094

-0.375

0.36%

4,605.22

16.03

0.35%

10,155.90

-317.19

3.03%

16,803.76

0.00

0.00%

1.361

0.012

0.89%

101.53

0.05

0.05%

90.06

2.25

2.56%

882.00

15.80

1.82%

BUSINESS NEWS

INVESTING

PERSONAL FINANCE AT WALLETPOP

SMALL BUSINESS

Array Biopharma and AstraZeneca announce new Ph. 2 development plans for the investigational anti-cancer drug AZD6244

Briefing.com

Posted: 2008-05-16 00:35:00

Co and AstraZeneca (AZN) announce plans for two additional randomized Ph. 2 trials for AZD6244 (ARRY-886). The trials, which will begin during 2H08, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244's activity as a single agent in previous monotherapy Phase 2 trials and on data from multiple preclinical studies.

Must Read?

0 %

0 %

0 VOTES

SHARE

Bookmark:

Recent Comments

Add your own Comments

advertisement

advertisement

More at BloggingStocks.com

Prudence Cuming Assoc./Getty Images

Headlines From AOL Money & Finance Partners

More Financial Times

BusinessWeek

More BusinessWeek.com

More SmartMoney

More Portfolio.com

More From Kiplinger.com

More TheStreet.com